Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 3/20 | 0.54 |
| ▸ | P2RY2 | P41231 | 4/20 | 0.41 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.41 |
| ▸ | POLA1 | P09884 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | TOP2A | P11388 | 4/20 | 0.35 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.35 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.34 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.34 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.34 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.34 |
| ▸ | P2RY6 | Q15077 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21418793 | 1.00 | DUT (0.54) | DUTP2RY2P2RY4POLA1CYP3A4 | |
| SCHEMBL21755901 | 0.92 | DUT (0.47) | DUTP2RY2P2RY4POLA1CYP3A4 | |
| SCHEMBL19813714 | 0.90 | DUT (0.52) | DUTP2RY2P2RY4POLA1CYP3A4 | |
| SCHEMBL16777673 | 0.89 | DUT (0.53) | DUTP2RY2P2RY4POLA1CYP3A4 | |
| SCHEMBL20053425 | 0.89 | DUT (0.45) | DUTP2RY2P2RY4POLA1CYP3A4 | |
| SCHEMBL860462 | 0.89 | DUT (0.45) | DUTP2RY2P2RY4POLA1CYP3A4 | |
| SCHEMBL860463 | 0.89 | DUT (0.45) | DUTP2RY2P2RY4POLA1CYP3A4 | |
| SCHEMBL19614658 | 0.89 | DUT (0.55) | DUTP2RY2P2RY4POLA1CYP3A4 | |
| SCHEMBL19614657 | 0.89 | DUT (0.55) | DUTP2RY2P2RY4POLA1CYP3A4 | |
| SCHEMBL19813722 | 0.89 | DUT (0.51) | DUTP2RY2P2RY4POLA1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11008361-B2 | Liver-specific delivery-based anti-hepatitis C prodrug nucleoside cyclo-phosphate compound and uses thereof | ZHEJIANG PALO ALTO PHARMACEUTICALS, INC. (CN) | 2021-05-18 | — | — | US | disclosed |
| US-20200048299-A1 | LIVER-SPECIFIC DELIVERY-BASED ANTI-HEPATITIS C PRODRUG NUCLEOSIDE CYCLO-PHOSPHATE COMPOUND AND USES THEREOF | ZHEJIANG PALO ALTO PHARMACEUTICALS,INC (CN) | 2020-02-13 | — | — | US | disclosed |
| WO-2016035006-A1 | NOVEL NUCLEOTIDE ANALOGS, PROCESS FOR THE PREPARATION OF SOFOSBUVIR AND ITS ANALOGS, NOVEL FORMS OF SOFOSBUVIR AND SOLID DISPERSION OF SOFOSBUVIR | DR. REDDY’S LABORATORIES LIMITED (IN) | 2016-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200048299-A1 | LIVER-SPECIFIC DELIVERY-BASED ANTI-HEPATITIS C PRODRUG NUCLEOSIDE CYCLO-PHOSPHATE COMPOUND AND USES THEREOF | SLC6A7, DCTPP1, PYGL | DUT 436/4885P2RY2 1340/4885P2RY4 878/4885 |
| US-11008361-B2 | Liver-specific delivery-based anti-hepatitis C prodrug nucleoside cyclo-phosphate compound and uses thereof | SLC6A7, DCTPP1, PYGL | DUT 436/4885P2RY2 1340/4885P2RY4 878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.